- Trials with a EudraCT protocol (99)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
99 result(s) found for: Type 1 Diabetes AND Continuous glucose monitoring.
Displaying page 1 of 5.
EudraCT Number: 2008-002711-41 | Sponsor Protocol Number: VER7200410 | Start Date*: 2008-08-15 | |||||||||||
Sponsor Name:University of Dundee (Research & Innovation Services) | |||||||||||||
Full Title: “Tight glycaemic control” and the risk of hypoglycaemia: Is this different between multiple injections versus insulin pump therapy? A UK multi-centre, open randomised control trial. | |||||||||||||
Medical condition: Type 1 diabetes mellitus in children and adolescents | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003869-17 | Sponsor Protocol Number: 0893-005 | Start Date*: 2006-09-25 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Multi-center, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Panel Study to Assess the Safety, Tolerability, and Glucose-Lowering Efficacy of MK-0893 in Patients With Type 2 Diabetes Me... | |||||||||||||
Medical condition: Type II Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005353-82 | Sponsor Protocol Number: LPS17375 | Start Date*: 2022-05-09 | |||||||||||
Sponsor Name:Sanofi-Aventis S.A | |||||||||||||
Full Title: Prospective study to assess with Continuous Glucose Monitoring (CGM) the efficacy and safety of switching to insulin glargine 300 U/ml from insulin glargine 100 U/ml in Type 2 Diabetes (T2DM) patie... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018979-16 | Sponsor Protocol Number: SAXA24011980GLIPTIN | Start Date*: 2010-08-23 | |||||||||||
Sponsor Name:University Hospital Erlangen | |||||||||||||
Full Title: EFFECTS OF SAXAGLITPIN ON ENDOTHELIAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES | |||||||||||||
Medical condition: diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002070-36 | Sponsor Protocol Number: GLU-005 | Start Date*: 2004-12-22 | |||||||||||
Sponsor Name:Metcon Medicin AB | |||||||||||||
Full Title: Efficacy of MM005-Granulae as prophylaxis for nocturnal hypoglycemia in insulin treated Type 1 diabetic subjects. A double-blind, randomized, placebo-controlled phase II multi-center study in three... | |||||||||||||
Medical condition: Diabetes type I | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004080-43 | Sponsor Protocol Number: LPS16664 | Start Date*: 2020-02-25 | |||||||||||
Sponsor Name:sanofi-aventis Private Co. Ltd. | |||||||||||||
Full Title: Suliqua® (iGlarLixi) in Participants uncontrolled on basal insulin to Evaluate the change of time in target Range By using Continuous Glucose Monitoring | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004760-37 | Sponsor Protocol Number: NA | Start Date*: 2015-12-23 | |||||||||||
Sponsor Name:Riitta Veijola | |||||||||||||
Full Title: Incretin-based therapy in non-symptomatic, early diagnosed type 1 diabetics | |||||||||||||
Medical condition: Type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024054-11 | Sponsor Protocol Number: NN1218-3854 | Start Date*: 2016-05-23 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to NovoRapid® in Adults with Type 1 Diabetes | |||||||||||||
Medical condition: Diabetes Mellitus, Type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) BE (Completed) FR (Completed) SI (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000743-68 | Sponsor Protocol Number: LDX0122 | Start Date*: 2022-12-13 | |||||||||||
Sponsor Name:DOMPé FARMACEUTICI S.P.A. | |||||||||||||
Full Title: A phase II randomized, placebo-controlled, double-blinded, 2-parallel arm, clinical trial evaluating Ladarixin 400 mg twice a day as adjunctive therapy to improve glycemic control in overweight ins... | |||||||||||||
Medical condition: overweight insulin-resistant patients with type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001702-33 | Sponsor Protocol Number: CV181-369 | Start Date*: 2016-01-07 | |||||||||||||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||||||||||||
Full Title: A 24-week International, Multicenter, Randomized, Open-Label, Active-Controlled, Parallel Group, Phase 3b Trial with a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-admini... | |||||||||||||||||||||||
Medical condition: Type 2 diabetes mellitus and inadequate glycemic control on a stable dose of metformin | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Completed) CZ (Completed) ES (Completed) SE (Completed) DK (Completed) DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-006118-15 | Sponsor Protocol Number: CLAF237ADE07 | Start Date*: 2012-06-13 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: Multicentric cross-over trial to assess the glycemic profiles on 8 weeks of vildagliptin and sitagliptin treatment, each, in type-2 diabetic patients with a pre-existing cardiovascular disease pre-... | |||||||||||||
Medical condition: type-2 diabetes mellitus with pre-existing cardiovascular disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000474-16 | Sponsor Protocol Number: NN1436-4480 | Start Date*: 2020-11-19 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A 26-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with bolus insulin with or without non-insulin anti-d... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000454-10 | Sponsor Protocol Number: NN1436-4478 | Start Date*: 2021-02-09 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A 26-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin degludec, both with or without non-insulin anti-diabetic drugs, in subjects with type 2 diabetes... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004120-11 | Sponsor Protocol Number: GN17DI706 | Start Date*: 2020-05-05 | |||||||||||
Sponsor Name:NHS Greater Glasgow and Clyde [...] | |||||||||||||
Full Title: Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide and Dapagliflozin | |||||||||||||
Medical condition: Type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002374-27 | Sponsor Protocol Number: NN1436-4625 | Start Date*: 2021-04-01 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and safety of once weekly insulin icodec compared to once daily insulin degludec 100 units/mL, both in combination with insulin aspart, in adults with type 1 diabetes. A 26-week, randomis... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001922-14 | Sponsor Protocol Number: 1245.69 | Start Date*: 2015-05-27 | |||||||||||
Sponsor Name:Boehringer Ingelheim Ltd | |||||||||||||
Full Title: A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to inSulin thErapy over 5... | |||||||||||||
Medical condition: Type 1 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) ES (Completed) SE (Completed) FI (Completed) DK (Completed) DE (Completed) NL (Completed) CZ (Completed) AT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003076-35 | Sponsor Protocol Number: F3Z-VI-S019 | Start Date*: 2006-09-26 | |||||||||||
Sponsor Name:Eli Lilly and Company Ltd. | |||||||||||||
Full Title: Treatment Strategies in Patients with Type 2 Diabetes Mellitus Not Achieving Glycemic Control while on Therapy with Premixed Insulin Analogues and Metformin: A Comparison of Insulin Lispro MM Inte... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002966-15 | Sponsor Protocol Number: LDX0419 | Start Date*: 2021-02-22 | |||||||||||
Sponsor Name:Dompe farmaceutici s.p.a. | |||||||||||||
Full Title: A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and pres... | |||||||||||||
Medical condition: New-onset Type 1 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001926-71 | Sponsor Protocol Number: LDX0319 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Dompe farmaceutici s.p.a. | |||||||||||||
Full Title: A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the effect and safety of 400 mg twice a day oral ladarixin in patients with recent onset type 1 diabetes and a l... | |||||||||||||
Medical condition: Recent onset Type 1 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) SI (Completed) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005281-34 | Sponsor Protocol Number: NN1535-4591 | Start Date*: 2022-01-21 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A 52 week study comparing the efficacy and safety of once weekly IcoSema and once weekly insulin icodec, both treatment arms with or without oral anti diabetic drugs, in participants with type 2 di... | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) NO (Completed) BE (Completed) BG (Completed) PT (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
